Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 60498
Gene Symbol: IGAN1
IGAN1
0.100 GeneticVariation disease BEFREE Forty-three patients with primary glomerulonephritis were identified: 25 had biopsy-proven disease (11 immunoglobulin A (IgA) nephropathy; eight mesangial proliferative glomerulonephritis without IgA deposits; four focal segmental glomerular sclerosis; two membranous nephropathy), and 18 had clinical glomerulonephritis. 16528253 2006
Entrez Id: 60498
Gene Symbol: IGAN1
IGAN1
0.100 Biomarker disease BEFREE Here we describe the rates and timing of post-transplant glomerulonephritis recurrence for IgA nephropathy, focal segmental glomerulosclerosis, mesangiocapillary GN and membranous GN based on 28 years of ANZDATA registry transplant data. 30509213 2018
Entrez Id: 60498
Gene Symbol: IGAN1
IGAN1
0.100 Biomarker disease BEFREE Human leukocyte antigens (HLA) have been found to be associated with the pathogenesis of autoimmune diseases, allergies and inflammatory bowel diseases, and there are emerging evidences of correlations between HLA genotypes and renal diseases such as diabetic nephropathy, IgA nephropathy, and glomerulonephritis. 26518904 2015
Entrez Id: 60498
Gene Symbol: IGAN1
IGAN1
0.100 Biomarker disease BEFREE In the plateau group, IgA nephropathy (IgAN) was the major primary glomerulonephritis (GN) pathology. 30027800 2018
Entrez Id: 60498
Gene Symbol: IGAN1
IGAN1
0.100 GeneticVariation disease BEFREE Mutations in the complement factor H gene (CFH) region associate with renal-limited mesangial proliferative forms of glomerulonephritis including IgA nephropathy (IgAN), dense deposit disease (DDD) and C3 glomerulonephritis (C3GN). 24586071 2014
Entrez Id: 60498
Gene Symbol: IGAN1
IGAN1
0.100 Biomarker disease BEFREE Peripheral Th1/Th2 ratio was significantly higher in ANCA-associated GN (19.4 +/- 9.4, mean +/- SD, n = 10), than those in healthy controls (7.6 +/- 4.1, n = 27), IgA nephropathy (9.6 +/- 5.6, n = 45), membranous nephropathy (7.1 +/- 4.4, n = 13), minimal-change nephrotic syndrome (8.2 +/- 4.5, n = 13) and focal segmental glomerulosclerosis (8.3 +/- 3.9, n = 10) (p < 0.01, each). 12834170 2003
Entrez Id: 60498
Gene Symbol: IGAN1
IGAN1
0.100 Biomarker disease BEFREE Renal tissue samples from patients of glomerulonephritis with more than 30% cell or cell-fibrous crescents, including lupus nephritis (LN, n=14), anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV, n=14), IgA nephropathy(IgAN) (n=11), Henoch Schonlein purpura glomerulonephritis(HSPGN)(n=8)were included in this study. 28554749 2017
Entrez Id: 60498
Gene Symbol: IGAN1
IGAN1
0.100 Biomarker disease BEFREE The present review highlights recent advances in the role of miRNAs in the pathogenesis of primary and secondary glomerulonephritides such as IgA nephropathy, focal segmental glomerular sclerosis, lupus nephritis and diabetic nephropathy. 25881669 2015
Entrez Id: 60498
Gene Symbol: IGAN1
IGAN1
0.100 GeneticVariation disease BEFREE The process of IgA biosynthesis, interaction with receptors, and clearance can be disrupted in certain pathologies, like IgA nephropathy, which is the most common form of glomerulonephritis worldwide. 31818032 2019
Entrez Id: 60498
Gene Symbol: IGAN1
IGAN1
0.100 AlteredExpression disease BEFREE To elucidate the role of sEH in glomerulonephritis, we first determined the expression of sEH in human kidney by examining biopsies from 153 patients with a variety of glomerulonephritis, including minimal-change, membranous, and IgA nephropathy. 23152298 2013
Entrez Id: 60498
Gene Symbol: IGAN1
IGAN1
0.100 Biomarker disease BEFREE Two underwent renal biopsy (1 IgA nephropathy; 1 focal glomerulosclerosis); four were diagnosed as having clinical glomerulonephritis. 1323067 1992
Entrez Id: 60498
Gene Symbol: IGAN1
IGAN1
0.100 GeneticVariation disease BEFREE While the risk pattern did not differ in lupus and non-lupus GN, a significantly higher OR of PE was observed in IgA nephropathy (OR 28.09 versus other GN); risk for pre-term delivery was not increased (OR 0.27 (0.06-1.11)), thereby suggesting "late-maternal" PE. 28279626 2017